Cingulate price target raised to $8 from $3.50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Cingulate to $8 from $3.50 and keeps a Buy rating on the shares. The analyst says the CTx-2103 clinical entry authorization application could be filed in the first half of 2024, though visibility regarding the next steps remains uncertain.